News Tag: mfn-cus-disclaimer

XVIVO Perfusion avser att genomföra en riktad nyemission av aktier

  • 15:31

XVIVO Perfusion AB (publ) (“XVIVO” eller “Bolaget”) (Nasdaq Stockholm: XVIVO) avser att genomföra en nyemission av aktier till ett belopp motsvarande cirka 250 miljoner kronor riktad till svenska och internationella institutionella investerare (den ”Riktade Emissionen”). XVIVO har anlitat Carnegie Investment Bank AB (publ) (”Carnegie”) och Bryan, Garnier & Co (”Bryan, Garnier & Co”) som Joint Bookrunners i samband med den Riktade Emissionen.

Read more

XVIVO Perfusion intends to carry out a directed issue of shares

  • 15:31

XVIVO Perfusion AB (publ) (“XVIVO” or the “Company”) (Nasdaq Stockholm: XVIVO) intends to carry out a new issue of shares with an amount of approximately SEK 250 million directed to Swedish and international institutional investors (the “Directed Issue”). XVIVO has appointed Carnegie Investment Bank AB (publ) (“Carnegie”) and Bryan, Garnier & Co (“Bryan, Garnier & Co”) to act as Joint Bookrunners in connection with the Directed Issue.

Read more

XVIVO has entered into an agreement to acquire the US organ recovery company Star Teams and finances the acquisition through a private placement of new shares

  • 15:30

XVIVO Perfusion AB (publ) (“XVIVO” or the “Company”) has today signed an agreement to acquire 100 percent of the shares in the US organ recovery company Star Teams Inc. (“Star Teams”) for an initial purchase price of USD 12.61 million with an additional potential earn-out payment of up to USD 13.75 million , paid out earliest in 2024. Star Teams delivers an integrated data-driven approach to organ recovery in which the company’s surgeons are on call 24/7, 365 days per year, to retrieve organs and deliver them safely to transplant centers around the US with a mission to save lives. Through the acquisition, XVIVO extends its product portfolio with value-added services within the organ transplantation industry, becoming a transplant powerhouse as the most comprehensive turnkey provider for transplant centers, driving the adoption of machine perfusion. The acquisition is to be financed by a new share issue of approximately SEK 250 million directed to Swedish and international institutional investors through an accelerated book-building procedure, which is expected to commence today.

Read more